Kornimate/medical-research-clean huggingface dataset:
improving help-seeking for depression care in nepal

Conditions: Help-Seeking Behavior; Depression

Summary: depression is a serious public health concern worldwide due to its high prevalence rate and significant emotional and financial burden on individuals, their families, and society. there is a substantial gap between the number of people in need of treatment for depression and those who actually receive it. the recent world health organization (who) world mental health survey revealed that 86.3% of people with anxiety, mood, or substance disorders in lower-middle-income countries did not receive any treatment in the past 12 months. this study aims to evaluate a community-based intervention to address demand-side barriers by improving mental health literacy, dispelling myths and misconceptions about depression, changing negative attitudes towards depression care, and promoting help-seeking behavior.

it is estimated that more than 300 million people worldwide are experiencing depression, which is about 4.4% of the world's population. despite the availability of evidence-based treatment, it is reported that 86.3% of people with anxiety, mood, or substance disorders in lower-middle-income countries received no treatment in the past 12 months. among people who receive treatment for depression, only one out of 27 persons receive minimally adequate treatment in low- and middle-income countries (lmics). despite being the major contributor to the overall global burden of disease, depression receives less or no health priority in many lmics, where more than 80% of people with depression reside. this study will take place in two municipalities in morang district, eastern nepal. female community health volunteers will administer the intervention to individuals identified with depression using the locally developed and validated community informant detection tool (cidt). participants who receive the intervention will be followed up after one month to evaluate their help-seeking behavior (primary outcome) and after three months to assess treatment adherence, a secondary objective of the study. the study will assess the effects and interactions of four intervention components (information on depression, available treatments, stigma and myths, and life transformation experiences) on the primary outcome of help-seeking behavior and secondary outcomes such as treatment adherence. the severity of depression symptoms will be assessed using the validated phq-9, and knowledge and attitudes toward depression will be evaluated to assess mediation effects.

Eligibility criteria:
inclusion criteria: * being an adult aged 18 or older residing in kanepokhari rural municipality or patharisanischare municipality, * those detected through the cidt * providing consent for participation * being proficient in speaking and understanding nepali exclusion criteria: * people with already receiving mental health services * having severe mental illness\] * participants below the age of 18 years, * participants outside of kanepokhari and pathari-sanischare municipality

Keywords: depression help-seeking behaviour demand side barriers stigma nepal
non-inferiority comparison of efficacy and safety of penciclovir 10mg/g to acyclovir 50mg/g in the treatment of recurrent herpes labialis

Conditions: Herpes Labialis

Summary: herpes labialis is the most common recurrent manifestation of herpes simplex. the purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for herpes labialis in comparison to acyclovir 50mg/g.

study design: • double blinded non-inferiority prospective parallel-group, intend to treat trial. study design: * experiment duration: 10 days * 3 visits (days 1,5 and 10) * erythema, papule, vesicle, ulcer, crust and healed skin evaluation * adverse events evaluation

Eligibility criteria:
inclusion criteria: 1. patients must be able to understand the study procedures agree to participate and give written consent. 2. patients with clinical diagnosis of recurrent herpes labialis and are in the prodromal period (stinging, itching, burning and erythema) at the onset of signs / symptoms in the last 12-24 hours; 3. no history of reaction to topical products; exclusion criteria: 1. pregnancy or risk of pregnancy. 2. lactation 3. use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study.) 4. sunlight over exposure in the last 15 days. 5. any pathology or past medical condition that can interfere with this protocol. 6. ainh use, hormonal anti-inflammatory, analgesic and immunosuppressive drugs (in the last 30 days and during the study); 7. patients with immunodeficiency and/or immunosuppressive disease; 8. sunlight exposure in the last 15 days; 9. hypersensitivity to components of the formula; 10. other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.

Keywords: herpes simplex
clinical study to evaluate the safety, tolerance and pharmacokinetic characteristics of single administration of hrs-5635 injection in chinese healthy subjects and the safety, tolerance, pharmacokinetics and antiviral effect of multiple administration in patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of hrs-5635 in healthy adults and chronic hepatitis b. to explore the reasonable dosage of hrs-5635.


Eligibility criteria:
inclusion criteria: 1. understand the specific process of the test, voluntarily participate in the test, and sign the informed consent form in writing（in healthy people and chronic hepatitis b）. 2. age 18-55 (including boundary value) （in healthy people）; age 18-65 (including boundary value) （in chronic hepatitis b）. 3. male weight ≥ 50 kg, female weight ≥ 45 kg, body mass index (bmi) 18\~28 kg/m2 (including boundary value) （in healthy people）. 4. normal or abnormal vital signs, physical examination, laboratory examination, chest radiograph, etc. have no clinical significance（in healthy people）. 5. subjects (including partners) are willing to voluntarily take effective contraceptive measures within 6 months after screening and the last study drug administration（in healthy people）. exclusion criteria: 1. those suffering from any clinical serious disease such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormality, or any other disease that can interfere with the test results（in healthy people）. 2. previous history of malignant tumor（in healthy people）. 3. those who have digestive system disease or serious digestive system disease at present or in the near future (within one month), and the researcher believes that it may affect drug absorption or have safety risk（in healthy people）. 4. those who have serious infection, serious injury or major surgery within 3 months before administration; those who plan to undergo surgery during the trial and within two weeks after the end of the trial（in healthy people）. 5. serious cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled conditions, including but not limited to myocardial infarction, unstable angina pectoris, heart failure, and moderate stroke（（in chronic hepatitis b））. 6. clinically significant liver diseases caused by other causes (such as alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced liver injury, alcoholic hepatitis, etc.); （in chronic hepatitis b）.
effect of elastic chest compression on functional exercise capacity and respiratory performance in patients with copd

Conditions: COPD; Hyperinflation

Summary: the goal of this clinical trial is to investigate the effects of elastic chest compression on functional exercise capacity and respiratory performance of patients with copd. the main questions it aims to answer are: is there difference in functional exercise capacity and respiratory performance without or with the use of elastic upper chest compression? is there difference in functional exercise capacity and respiratory performance between the use of elastic upper chest compression and elastic lower chest compression? participants will: be evaluated under three conditions on three different days: without elastic compression, with upper chest compression, and with lower chest compression, with the order of compression application randomly assigned. the functional capacity and respiratory muscle performance of all patients will be evaluated. the days for evaluation will be at least three days apart from each other.

participants will be evaluated under three conditions: without elastic compression, with upper chest compression, and with lower chest compression, with the order of compression application randomly assigned. a red theraband will be used to apply compression to the upper and lower regions of the chest. for a standardized approach to apply compression, the top edge will be aligned with the 3rd intercostal space for the upper chest compression, while the central horizontal part will line up with the xiphoid process of the sternum for the lower chest compression. after exhaling to the eelv, the circumferences of the upper and lower chest regions will be measured, using the 3rd intercostal space as the measurement mark for the upper chest and the xiphoid process of the sternum as the measurement marks for the lower chest. the thera-band will be adjusted to 90% of the measured circumferences, ensuring it is securely fastened and standardized resistance is applied consistently to the thoracic regions of interest throughout the study. after chest compression is applied, participants will undergo measurements for functional exercise capacity and respiratory muscle performance.

Eligibility criteria:
inclusion criteria: * at least 20 years old * has a clinical diagnosis of copd without infection or acute exacerbation in the previous four weeks * is capable of cooperating with the required tests and measurements of the study exclusion criteria: * has any clinical diagnosis that could affect test outcomes (e.g., neuromyopathy) * has experienced unstable angina or an acute myocardial infarction within the last month * has adjusted copd related medication within the last month * a mini-mental state examination (mmse) score below 24

Keywords: chronic obstructive pulmonary disease dynamic hyperinflation elastic chest compression functional exercise capacity respiratory performance
personalized therapy of patients suffering from rare genodermatoses

Conditions: Rare Diseases

Summary: rare skin diseases are generally defined as serious life-threatening, progressive chronic diseases of the skin that occur extremely rarely (i.e., 5 in 10,000 people are affected). more than 80% are hereditary. in most cases, late diagnosis and the lack of therapeutic strategies also contribute to severe disease progression. therefore, new therapeutic options are urgently needed and with them knowledge of the underlying mechanisms of disease development. the aim of this project is to better understand disease mechanisms and to identify new pathways and drug targets that will improve patient care or therapy. in order to investigate the mechanisms of disease development, it is necessary to isolate biological material, i.e. blood and affected skin tissue from patients. for this purpose, adults 18 years of age and older with a congenital rare skin disease are included. we take blood and (lesional) skin biopsies from patients to perform immunoprofiling, as well as cell biological studies with the patient's cells. the risk for the patients is low, as only peripheral blood and skin biopsies are taken. potential risks include bruising and pain as well as infection, postoperative bleeding, wound infection or delayed wound healing, pain, and scarring. the samples are pseudonymized and stored with the pseudonym only. cells and skin samples are only preserved with the prior consent of the patient.


Eligibility criteria:
inclusion criteria: * age of 18 * rare disease is known or suspected * patent consent exclusion criteria: * none
comparative effects of focused and radial shock-wave therapies in hip osteoarthritis.

Conditions: Hip Osteoarthritis

Summary: there is no scientific study in the literature regarding the use of shock wave therapy in hip osteoarthritis. in this study, we aim to investigate both the effectiveness of eswt and which type of eswt can be more effective in hip osteoarthritis.


Eligibility criteria:
inclusion criteria: * unilateral or bilateral hip osteoarthritis exclusion criteria: * other disorders that are contraindications for shockwave therapy, not have received eswt treatment before
anti-inflammatory effect of pre-operative stimulation of the cholinergic anti-inflammatory pathway

Conditions: Postoperative Ileus

Summary: hypothesis: prucalopride can mimic electrical stimulation of the abdominal vagus nerve and has an anti-inflammatory effect. aims: in the present pilot study, the investigators want to evaluate the anti-inflammatory effect of prucalopride. the following aims are formulated: 1. to show that prucalopride has a similar inflammatory effect as abdominal vagus nerve stimulation (vns) 2. to evaluate whether prucalopride leads to accelerated post-operative recovery


Eligibility criteria:
inclusion criteria: * patients undergoing partial or full resection of the pancreas due to a benign or malignant tumor exclusion criteria: * adjuvant radiotherapy * evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory results, including an abscess or cholecystitis) * chronic pancreatitis * pancreatic polypeptide producing endocrine tumor * american society of anesthesiologists physical-health status classification (asa-ps)\>3 * poorly regulated diabetes (\>200 mg/dl (=11 mmol/l))

Keywords: prucalopride vagus nerve stimulation postoperative ileus
impedancemetry in patients monitored for pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for pulmonary hypertension

cardiac impedancemetry is a technique that allows an electrical representation of cardiac flows. to do this, 6 electrodes are applied to the thorax and a low intensity and high frequency electrical current is transmitted. the impedance is recorded and the variations of the impedance represent the changes in intra-thoracic volume and thus the volume of systolic ejection. this measurement can be done at rest but also during exercise during the walking test. a test of the no / co coupled transfer measurement is also performed. the devices that will be used in this project are the physio-flow® system and masterscreen no / co coupled transfer measurement device

Eligibility criteria:
inclusion criteria: * patient over 18 years and under 80 years * patients who have been diagnosed with pah (group 1 ph according to the nice 2013 classification) or post-embolic pulmonary hypertension (group 4 ph) under medical treatment; * htp incident or prevalent less than 6 months * patient coming for follow-up or emergency consultation or hospitalization with a clinical examination and a walking test * patient affiliated to a health insurance scheme * patient having signed informed consent exclusion criteria: * subjects under juridical protections or tutelage measure * pregnant or lactating woman * pulmonary hypertension du to cardiac pathology, chronic respiratory disease, or uncertain determinism. * pulmonary hypertension of group 4 treated surgically or endoscopically. * pulmonary hypertension incident or prevail for 6 months or more * contraindication to impedancemetry * inability to perform a walking test

Keywords: pulmonary hypertension impedancemetry cardiac output
recurrence of acute alcoholic pancreatitis

Conditions: Recurrent Acute Pancreatitis

Summary: previously our retrospective study showed that almost half of the patients with acute alcoholic pancreatitis had a recurrent attack in the long-term, mild pancreatitis and young age being risk factors for recurrence. the aim of this prospective follow-up study was aimed to find out the risk factors in detail.

patients admitted to tampere university hospital for first acute alcoholic pancreatitis were included. the diagnostic criteria for acute pancreatitis were epigastric pain, serum amylase \> 3 x upper normal range, elevated serum crp and signs of acute pancreatitis in imaging. other etiologies were excluded. alcohol consumption and dependency were detected. serum and fecal markers of the endocrine and exocrine function and secretin stimulated mrcp were studied. the patients were followed median 38 (25 - 61) months for the recurrences and had a follow up visit at two years to investigate trends in the alcohol consumption.

Eligibility criteria:
inclusion criteria: * patients who survived their first acute alcoholic pancreatitis. the diagnostic criteria for acute pancreatitis were epigastric pain, serum amylase \> 3 x upper normal range, elevated serum crp and signs of acute pancreatitis in imaging. other etiologies were excluded. * high alcohol consumption was detected
a novel robotic system for motor-cognitive exercise for patients with parkinson's disease

Conditions: Parkinson Disease, Idiopathic

Summary: the objective of this study is to test a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with parkinson's disease (pd). this pilot experiment will involve the collection of both subjective user evaluation measures and objective motor and cognitive measures.

participants \& protocol: recruitment: advertising ads in movement disorders units in hospitals and medical centers in the south, as well as through the help of the parkinson's association. the study will be conducted with 15 pd patients, aged 50-75, at the adi negev clinic. each patient will use the robotic system five times, with each session lasting 30 minutes. the intervention plan incorporates principles of effective rehabilitation practice, including repeated practice, goal-oriented practice, variable difficulty, rhythmic cueing, and social interaction. before the research begins, participants will sign an informed consent form. baseline and pre-post tests: assessments including the moca, demographic data, clinical data, color trails test (ctt), motor updrs, box \& blocks test, and cognitive reserve index questionnaire (criq) will be collected before the first session by an occupational or physical therapist. after the fifth session, post-intervention assessments will include motor updrs, box \& blocks test, ctt, system usability scale (sus), intrinsic motivation inventory (imi), and a satisfaction questionnaire. hypothesis: it is hypothesized that motor and cognitive training using the robots will improve the patients' clinical symptoms, as evidenced by pre-post test results. novelty \& impact: this is the first socially assistive robotic platform developed specifically for people with pd. if successful, this platform could be incorporated into the clinical toolbox at adi negev and other centres. additionally, this study will be the first to use the cognitive reserve index questionnaire (criq) in hebrew for people with pd. the potential impact of this project is twofold: testing a new rehabilitation tool and a screening tool for pd patients.

Eligibility criteria:
inclusion criteria: * signing the informed consent form * men and women in ages 50-75 * hebrew speakers * have idiopathic parkinson's disease * hoehn and yahr 3 and below * moca test 23 and above exclusion criteria: * patients with parkinson's plus syndromes * pd patients who suffer from unrelated neurological symptoms. * orthopedic problems of the upper limb * recent surgery conducted on the upper limb * uncorrected vision problems * uncorrected severe hearing loss

Keywords: parkinson-disease sar rehabilitation motor-cognitive pd
predictive factors affecting the efficacy of local tetracycline injection for treatment of post-mastectomy seroma.

Conditions: Post-mastectomty Seroma

Summary: female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. then after 5 days the patient were examined again for seroma re-collection or the presence of complications. the amount of seroma aspirated in each session.

in this study, 18 patients with established diagnosis of post-mastectomy seroma were included. all of them were females undergoing modified radical mastectomy where seroma appeared after drain removal. the age, co-morbidities, total leukocytic count (as an indicator of infection), serum albumin and tumour size and pathology for all of them were recorded. then we interfered with our tetracycline injection technique for the treatment of seroma. all the patients were consented regarding this therapeutic technique explaining the expected possible occurrence of some pain during and after injection, other complications like wound infection or flap necrosis necessitating further intervention. moreover, repetition of the technique may be needed in our technique the following was adopted: 1. first, the seroma fluid was aspirated completely using a 20 cc syringe while the patient lying flat and the needle inserted in the most dependent area 2. then, 10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed. 3. after completion of injection, a crepe bandage was applied over the mastectomy area (flaps covering the seroma bed) 4. then after 5 days the patient were examined again for seroma re-collection or the presence of complications as infection or flap necrosis. if there were any re-collection, the tetracycline injection procedure would be repeated. the amount of seroma aspirated in each session in addition to the complications if present were recorded.

Eligibility criteria:
inclusion criteria: * any patient with post-mastectomy seroma following modified radical mastectomy after removal of drain * no signs of infection or flap necrosis exclusion criteria: * patients with post-mastectomy seroma following modified radical mastectomy with drain still in * if signs of infection or flap necrosis present